| Genevieve I Mcleod, MD | |
|
101 Memorial Hospital Dr Ste 200, Mobile, AL 36608-1787 | |
| (251) 414-5900 | |
| (251) 410-3021 |
| Full Name | Genevieve I Mcleod |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 101 Memorial Hospital Dr Ste 200, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407918493 | NPI | - | NPPES |
| 009940673 | Medicaid | AL | |
| 009940677 | Medicaid | AL | |
| 009940907 | Medicaid | AL | |
| 009940676 | Medicaid | AL | |
| 515-38555 | Other | AL | BCBS |
| 009940906 | Medicaid | AL | |
| 1407918493 | Other | AL | TRICARE SOUTH |
| 009940674 | Medicaid | AL | |
| 515-39830 | Other | AL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD.27728 (Alabama) | Secondary |
| 207R00000X | Internal Medicine | MD.27728 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Springhill Medical Center | Mobile, AL | Hospital |
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Providence Hospital | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Imc-hospitalists Llc | 2264727155 | 66 |
| Alabama Medical Group Pc | 6709152499 | 35 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
| Entity Name | Internal Medicine Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295787505 PECOS PAC ID: 7810801818 Enrollment ID: O20031114000068 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
| Entity Name | Inpatient Consultants Of Alabama, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235238916 PECOS PAC ID: 6709983422 Enrollment ID: O20110805000011 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
| Entity Name | Imc-hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669824934 PECOS PAC ID: 2264727155 Enrollment ID: O20160816002233 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
| Entity Name | Alabama Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841712684 PECOS PAC ID: 6709152499 Enrollment ID: O20171025000411 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Genevieve I Mcleod, MD 101 Memorial Hospital Dr, Ste 200, Mobile, AL 36608-1787 Ph: (251) 414-5900 | Genevieve I Mcleod, MD 101 Memorial Hospital Dr Ste 200, Mobile, AL 36608-1787 Ph: (251) 414-5900 |
News Archive
Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing' effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction Registry and provides preliminary data collected since its start in January of this year.
› Verified 7 days ago
Damian Joseph Collins, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Spring Hill Ave, Suite 100, Mobile, AL 36604 Phone: 251-435-1200 Fax: 251-435-6357 | |
Lenore Landers Pierce, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6801 Airport Blvd, Mobile, AL 36608 Phone: 251-639-5775 Fax: 251-631-3581 | |
Peter Chestnutt Coats, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6701 Airport Blvd, Suite A-101, Mobile, AL 36608 Phone: 251-633-8880 Fax: 251-634-4502 | |
Mr. Stephen Reeves Dill, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6801 Airport Blvd # 11n, Mobile, AL 36608 Phone: 251-445-2412 Fax: 850-981-1878 | |
Dr. Dale Scott Kirby Jr., MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd, Suite D-330, Mobile, AL 36608 Phone: 251-607-9797 Fax: 251-607-9761 | |
Sandeep Vidyadhar Bhadkamkar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6801 Airport Blvd, Mobile, AL 36608 Phone: 251-266-3580 Fax: 251-266-3581 | |
Reynaldo Rodriguez, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 Springhill Business Park, Mobile, AL 36608 Phone: 251-873-6192 Fax: 251-873-6193 |